A randomized, double-blind, placebo-controlled trial of niclosamide nanohybrid for the treatment of patients with mild to moderate COVID-19

Journal:

Nature Communications

Published:

2025-08-01

DOI:

10.1038/s41467-025-62423-4

Affiliations:

10

Authors:

12

Go to article

Institutions	Authors	Share
Dankook University (DKU), South Korea	3.500000	0.29
Yonsei University, South Korea	2.000000	0.17
Chungnam National University Sejong Hospital, CNU, South Korea	1.000000	0.08
Kyungpook National University (KNU), South Korea	1.000000	0.08
Korea University Ansan Hospital, South Korea	1.000000	0.08
Kyungpook National University Chilgok Hospital, South Korea	1.000000	0.08
Chosun University, South Korea	1.000000	0.08
Hyundai Bioscience Co., Ltd., South Korea	1.000000	0.08
The National Academy of Sciences, Republic of Korea (The NAS), South Korea	0.500000	0.04

Interested in Medical Microbiology?